Measurement of plasma and urinary levels of LXA4, resolvins, protectins and maresins may be used as prognostic markers in these diseases, while in multiple sclerosis; measurement of cerebrospinal fluid (CSF) levels of LXA4, resolvins, protectins and maresins can be used as markers of disease progression, response to therapy and its prognosis. Here, CD59 is linked to multiple sclerosis.